Genome Sequencing in World Record Time

Genome Sequencing in World Record Time

         Last month, a huge breakthrough was made in genome sequencing that could be the difference between critical NICU babies getting unnecessary treatments and, important procedures. Doctors and researchers at the Boston Children's Hospital and Roche Sequencing Solutions were able to do a full genome sequencing in right under four hours. This has shattered the old world record, 5 hours and 2 minutes, by over an hour.

    This new world record shows growth and maximization of efficiency within the genome sequencing world. This achievement uses a technology called Sequencing by Expansion. Sequencing by Expansion works to be more efficient, accurate, and reliable. By optimizing every step — from sample prep, to sequencing, to data analysis, the team was able to produce a full “variant call file” (VCF) in under four hours!

Why does this matter? In NICUs, time is often the extremely important. When a fresh baby shows signs of a genetic disorder, every second counts. Parents who are waiting days, or even weeks, for genetic testing can delay treatment or lead to unnecessary procedures. With SBX, doctors could send a blood sample in the morning and get a full genetic diagnosis by afternoon, This would be the start of same day, genetically backed up care.

This huge milestone means more than just a new record: it points to a future where genome sequencing becomes a regular and necessary care, especially for ill infants or patients with rare conditions. As SBX and other future sequencing platforms continue to improve, we may see a shift from targeted genetic tests to thorough, whole-genome diagnostics — reducing the “diagnostic odyssey” many families currently endure.

Studying genetics, this new world record is eye opening for the importance and input of real world usage of genome sequencing. This also helps recognize the usage of genome sequencing to help treat genetic disorders! 

Secondary Source: https://sequencing.roche.com/global/en/article-listing/sequencing-platform-technologies.html?utm_source=goolge&utm_medium=cpc&utm_campaign=DIA_SBX_awearness&utm_content=wgs&gad_source=1&gad_campaignid=22592607575&gbraid=0AAAAA_UEx4PJNawZm6gIXd7tDIqUXPY7F&gclid=Cj0KCQiAxJXJBhD_ARIsAH_JGjg77Z8xl7Anb9cFkEJClpbLwFuowFVnaBqYlJpoDyiI-WvfLELhrUUaAu1dEALw_wcB

Resources 

Thompson, Dennis. “New World Record Set for Fastest Human Whole Genome Sequencing.” HealthDay, 17 Oct. 2025, https://www.usnews.com/news/health-news/articles/2025-10-17/world-record-set-for-fastest-genome-sequencing

Roche Sequencing Solutions. “SBX Sequencing: Rapid Whole Genome Sequencing for Clinical Use.” Roche, 2025, https://sequencing.roche.com/global/en/article-listing/sequencing-platform-technologies.html?utm_source=goolge&utm_medium=cpc&utm_campaign=DIA_SBX_awearness&utm_content=DNAseq&gad_source=1&gad_campaignid=22592607575&gbraid=0AAAAA_UEx4PJNawZm6gIXd7tDIqUXPY7F&gclid=Cj0KCQiAxJXJBhD_ARIsAH_JGjirxBeyIUede5ih8r4q5AE1iBKvMROIobYiGbnSuQE7OKYPsnoihisaAkJGEALw_wcB

New Gene Therapy Brings Hope For Timothy Syndrome Blog #3

 Angelina Tadros

November 23, 2025

Genetics

Dr. Barbato

New Gene Therapy Brings Hope For Timothy Syndrome

Timothy syndrome is an extremely rare and severe genetic disorder caused by mutations in the CACNA1C gene, which encodes for a calcium channel that is crucial for normal cellular communication functioning. Calcium channels are active in many tissues, therefore the syndrome unfortunately affects multiple organ systems. Children with Timothy syndrome commonly present with dangerous cardiac arrhythmias (which is an abnormal heartbeat caused by malfunctioning electrical impulses, this could result in a heartbeat too fast, too slow, or irregular) neurodevelopmental delays, autism related behaviors, seizures, immune dysfunction, and physical abnormalities like syndactyly (webbed fingers or toes). This condition is usually life threatening in early childhood, and until now there hasn't been any treatments, or talk of treatments, to address the underlying cellular pathology.

A new NIH backed study published in Nature shows a new gene based treatment approach for Timothy syndrome that may be promising. Researchers at Stanford University used cells from patients to create brain organoids and assembloids, which are 3D tissue models that mimic human neural development. They then tested antisense oligonucleotides (ASOs), short strands of genetic material made to change gene expression, these specifically targeted the mutated exon 8a of CACNA1C that causes the disorder. By guiding cells to use the healthy version of the gene (exon 8), the ASO treatment successfully restored normal calcium channel functionality The improvements lasted for at least 90 days in human derived tissue, from the lab grown organoids and in organoids transplanted into rat brains.

This study is huge and represents a major step forward in this area of study, it uncovers something brand new that no one has been able to come close to as of now. This is major for Timothy disease and for gene based therapies targeting neurodevelopmental disorders in general. Restoring normal function in the calcium channel in the patient derived organoids shows that this mutation is reversible and provides a pathway to fully correct this rare disorder. This is important because this disorder was previously thought to be untreatable. While more work will obviously be needed in order to ensure safety and figure out how to successfully deliver this therapy to patients, these results provide hope and point to a possible first treatment that could change the course of the disease entirely and save many lives.

Figure 1

This image from the study published in Nature, shows transplanted human cortical organoids from people with Timothy Syndrome.

Sources

https://www.nimh.nih.gov/news/science-updates/2024/gene-based-therapy-restores-cellular-development-and-function-in-brain-cells-from-people-with-timothy-syndrome 

https://www.nature.com/articles/s41586-024-07310-6

https://techfinder.stanford.edu/technology/treatment-timothy-syndrome-using-antisense-oligonucleotide

Gene Therapy Infusions for Hemophilia B Patients

Recently, Penn Medicine published an article discussing how in the third phase clinical trial of an international study, adults with hemophilia B who received a single infusion of gene therapy saw a 71% decrease in the number of bleeding episodes. 

Hemophilia is a type of genetic disorder that slows the blood's clotting capabilities, which in turn causes spontaneous bleeding into critical areas such as joints. More specifically, hemophilia B is a type of hemophilia where clotting factor IX is not produced enough, so gene therapy is used to start the creation of clotting factor IX in the liver.

What the study showed was days after a patient's first infusion their body started to create clotting factor IX and after a year patients had a 71% reduction in spontaneous bleeding. On top of this over 45% of patients reported not having any bleeding after gene therapy. However, the most common adversive side effect of this was an immune system attack on liver cells, which can potentially be stopped with steroid treatment. The study is expected to continue for a minimum of five total years to observe all side effects, both long and short-term.

While this breakthrough could be critical for treating patients diagnosed with hemophilia B, it is important that the study continues to monitor all side effects before making this form of treatment widespread. This study as a whole is not only impressive for genetic medicine, but could be a breakthrough in treating a plethora of other diseases that have no known treatment as of now.

https://www.pennmedicine.org/news/news-releases/2024/september/gene-therapy-is-potentially-life-changing-for-hemophilia-b

https://www.pennmedicine.org/for-patients-and-visitors/patient-information/conditions-treated-a-to-z/hemophilia

https://www.pennmedicine.org/research-at-penn/gene-therapy

Does 'Jumping Genes' control certain cancers?

In an article on Medical Press's website, researchers from Washington University School of Medicine in St. Louis pointed out that many tumors are not just caused by a mutation of one of your genes but also by something called "jumping genes." "Jumping genes" are when DNA segments randomly move in a genome during human development. These researchers looked into many types of cancers and looked for these "jumping genes" in hope to further find a therapeutic way to try to treat these "jumping genes." After looking into about eight thousand tumors of about fifteen different cancers, they found that over one hundred jumping genes were pretending to be cancerous genes in about four thousand of those tumors. They also figured out that these types of genes are more aggressive than some cancer genes.

These researchers hope that further studies could help find a way to treat cancer and that this discovery is significant to different roles in cancer. I think that with further research it could open more doors to trying to fight and cure cancer in the future.

Companies Rush to to Develop 'Utterly Transformative' Gene Therapies

Imagine having a way to engineer your body to be able to fight off certain cancers. Much research and progress is being made in the field of gene therapy and is expected to be seen in leukemia patients within the next few months. Many companies and universities are racing to find ways to implement gene therapy techniques into other blood cancers such as lymphoma. Early studies in leukemia patients showed to be expensive and come with risks such as death due to raging fevers, low blood pressure and congested lungs. Doctors have learned to better control those side effects. The new leukemia treatment involves removing millions of white blood cells, specifically the T cells, which are often known as the soldiers of the immune system, from the blood stream, genetically engineering them to recognize and kill cancer, multiplying them, and then infusing them back into the  patient. Researchers are calling this T-cell treatment. The focus now is getting this treatment fully approved and advancing the treatment onto solid tumors in body organs such as the ovary, breast, prostate, pancreas, and lung. Research has shown that these solid tumors are less amendable to the altered cell treatment because they do not let the T-cells in easily; however, a combination approach of the altered cell method and something else is being worked on to advance the treatment. Researchers are continuously working on that something else every day.

Article

Head injuries can alter hundreds of genes and lead to serious brain diseases

Research has shown that head injuries can cause damage to hundreds of genes in the brain that can cause an increase of a risk to obtain a neurological or psychiatric disorder. In the article it is said that for the first time researchers believed they found the master genes that control several hundreds of other genes that are linked to Alzheimer's disease, Parkinson's disease, post-traumatic stress disorder, stroke, attention deficit hyperactivity disorder, autism, depression, schizophrenia and other disorders. From this finding, scientists can now learn how the master genes work in order to find new pharmaceuticals to treat these brain diseases. Damage to these master genes can cause a chain effect to cause damage to other hundreds of genes as well. The damage can change the gene in two ways; the first being proteins that are produced by these genes are irregular and the second being the number of expressed copies of a gene in a cell is changed. Both of these lead to a gene not working properly and causing the wrong form of protein to be produced, leading to diseases like Alzheimer's.

This new finding is huge for scientists! This is a step for them to find new ways to treat existing head injuries and diseases but also this is a step to find new ways to repair damaged cells in the brain.

Link to article
More info

Gene Associated With Higher Risk of MS

MS is a pretty big deal for people who have it because it is an autoimmune disorder which attacks the patient's nerve cells. It primarily is found in women aged from 20-50 years of age and could cause problems with their movements and bodily function. There is no cure, however treatments are available.
Researchers are currently putting more study into two particular genes, IL7R and DDX39B, which they claim that if one has variations of these two genes then it they could be up to 3 times more likely to get MS than one who does not. When there are two variations of these genes, then an overproduction of a protein called sIL7R is created, however the entire function of this protein is not entirely understood.
Overall, it's a step towards finding more effective treatments or possibly a cure.

 Article
More Info About MS

Facial-recognition software finds a new use: diagnosing genetic disorders

Inspired by observations made by Dr. Maximilian Muenke, it has been hypothesized that distinctive facial features may indicate the presence of a genetic disorder within an individual. He claims from his experience within the field, it is exceptionally easy for him to look at a patient and diagnose an existing condition such as William's syndrome, without any prior pedigree knowledge or medical testing. Although this immediate recognition may not always be completely accurate, it could give reason for someone to seek genetic testing or counseling if necessary. This skill is to be applied in the facial-recognition technology that is readily available today. Scientists hypothesize this technological breakthrough could be especially useful in instances where genetic testing is not available, and people who wish to have accurate medical help, or do not wish to pass such genetic disorders onto their children. Even in advanced societies, individuals with such syndromes could be misdiagnosed, and this will aid physicians in finding the best treatment for their patients. Face2Gene is a new program developed by FDNA, a Boston based start up, which is readily available to clinicians as a mobile app in which they may take photographs of their patients, with their consent, to be analyzed for possible syndromes they may have. A now quickly moving force, this new technology will have to be constantly updated and improved with the help of both developers and geneticists to keep the possible diagnoses as accurate and as useful to the public as possible. I believe if this technology is used properly, and can be as accurate as it claims, Face2Gene could really give clinicians, genetic counselors, and the public an edge on making actions to both treat and prevent deleterious and unwanted genetic syndromes. I hope this application is used as it is intended, and can genuinely make a difference in our society in dealing with these conditions.

STAT Newsletter